

**FAX TRANSMITTAL
TO THE UNITED STATES PATENT OFFICE**

Applicants Docket Number:
HMR2053 US NP

Applicants:
GUO et al

Serial No.
09/933,780

Filing Date:
August 21, 2001

Title of Invention:
Membrane Penetrating Peptides And Uses Thereof

CERTIFICATE OF TRANSMISSION	
I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, , via fax number 703-872-9306, on	
Date of Deposit	<u>April 23, 2004</u>
Printed Name of Person Signing Certificate <u>Delia Coughlin</u>	
Signature	<u>Delia Coughlin</u>

Total Number of Pages Sent: **2**

Attorney: **Michael J. Schmelzer**
Reg. No. **43,093**
Group Art Unit: **1653**
Examiner: **Anand U. Desai**

RECEIVED
CENTRAL FAX CENTER

TO: Mail Stop Non-Fee Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

OFFICIAL

APR 23 2004

Please acknowledge receipt of the below-listed documents for the above Application by returning this sheet, signed and dated, by return telefax to (908) 231-2626. If any fees are required, please charge our deposit account (18-1982) in the name of Aventis Pharmaceuticals Inc.

- | | |
|--|--|
| <input type="checkbox"/> Amendment, 37 CFR <u>1.111</u> | <input type="checkbox"/> Fee Transmittal |
| <input type="checkbox"/> Charge deposit account, in duplicate | <input type="checkbox"/> Petition under 37 CFR _____ |
| <input type="checkbox"/> Extension of Time Petition (in duplicate) | <input checked="" type="checkbox"/> Other <u>Response to Restriction Requirement</u> |
| <input type="checkbox"/> Issue Fee Transmittal & Advance Order | <input type="checkbox"/> Other _____ |
| <input type="checkbox"/> Maintenance Fee Transmittal | |

Receipt Confirmed:

Signed

Dated

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. www.aventis.com
NOTICE: The documents accompanying this telexopy transmission are intended only for the use of the individual or entity named above. If you have received this telexopy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Aventis Pharmaceuticals Inc. template (March 2001)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Guo et al.

Application No.: 09/933,780

Examiner: **Anand U. Desai**Art Unit: **1653**Filed: **August 21, 2001**Title: **MEMBRANE PENETRATING
PEPTIDES AND USES THEREOF****TELEFAX CERTIFICATE**

I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, Alexandria, VA 22313 at fax number 703-872-9306, on

April 23 2004
 Date of transmission
Debra Coughlin
 Signature: Debra Coughlin

RESPONSE TO RESTRICTION REQUIREMENT

RECEIVED
CENTRAL FAX CENTER


APR 23 2004

OFFICIAL

Mail Stop: Non-Fee Amendment
 Commissioner for Patents
 P. O. Box 1450
 Alexandria, VA 22313-1450

In response to the Restriction Requirement imposed by the Examiner in the above-identified case (Office Communication mailed April 15, 2004), Applicants hereby request reconsideration and withdrawal of the Restriction Requirement. In accordance with 37 CFR 1.143, Applicants hereby provisionally elect, Group I (Claims 1-10, and 18-21) for further prosecution in the event the Restriction Requirement is made final. Applicants reserve the right to pursue the remaining non-elected subject matters in one or more timely filed divisional applications. Applicants also reserve the right to resubmit the withdrawn claims in accordance with the provisions of MPEP § 821.04.

Respectfully submitted,


 Michael Schmelzer, Reg. No. 43,093

Attorney for Applicant

Aventis Pharmaceuticals Inc.
 Patent Department
 Route #202-206 / P.O. Box 6800
 Bridgewater, NJ 08807-0800
 Telephone (908) 231-4797
 Telefax (908) 231-2626

Aventis Docket No. **HMR2053 US NP**